Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Expenses (2016 - 2017)

Historic Accumulated Expenses for Northwest Biotherapeutics (NWBO) over the last 9 years, with Q1 2017 value amounting to $933000.0.

  • Northwest Biotherapeutics' Accumulated Expenses fell 2153.07% to $933000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $933000.0, marking a year-over-year decrease of 2153.07%. This contributed to the annual value of $901000.0 for FY2016, which is 3116.88% down from last year.
  • According to the latest figures from Q1 2017, Northwest Biotherapeutics' Accumulated Expenses is $933000.0, which was down 2153.07% from $901000.0 recorded in Q4 2016.
  • Northwest Biotherapeutics' Accumulated Expenses' 5-year high stood at $1.3 million during Q2 2016, with a 5-year trough of $655000.0 in Q2 2014.
  • Its 5-year average for Accumulated Expenses is $1.0 million, with a median of $1.1 million in 2013.
  • Per our database at Business Quant, Northwest Biotherapeutics' Accumulated Expenses tumbled by 8570.73% in 2013 and then skyrocketed by 8137.4% in 2015.
  • Northwest Biotherapeutics' Accumulated Expenses (Quarter) stood at $842000.0 in 2013, then surged by 43.82% to $1.2 million in 2014, then grew by 8.09% to $1.3 million in 2015, then crashed by 31.17% to $901000.0 in 2016, then rose by 3.55% to $933000.0 in 2017.
  • Its last three reported values are $933000.0 in Q1 2017, $901000.0 for Q4 2016, and $1.3 million during Q3 2016.